Annalists covering SSH will have to upgrade their buy rating to the extreme , the market will understand why very quickly , the FDA also will have no choice but to move quickly when no other promising treatment that works is in sight, SSH has a potential $90 billion addressable market all to itself , $100 plus per share can be closer than you think.
